Treatment volume of aedes albopictus with X rays generated from electrons

Irradiation is a common method used for sterilizing objects in several fields. In the entomology sector, insects are sterilized through irradiation and released in to the wild to sexually compete with the population at large reducing the chance for reproduction. This practice is the Sterile Insect Technique (SIT). Traditionally irradiation sources for SIT purpose are radioisotopes but many reasons compelled to getting efforts to develop other radiative technologies. Since gamma rays and electrons have similar sterilizing effects, the choice of source for SIT irradiation is based on considerations about penetration and environmental factors. Gamma irradiators are usually simpler to operate, and less expensive, than electron accelerators, at least within the range of power required for SIT applications. Currently, the increased difficulties to manage and ship radioisotopes is being successfully resolved by the introduction of novel X-ray irradiators that enable a safer use of irradiator machines and procedures for SIT applications. In the ENEA Frascati research center we developed irradiators for clinical radiotherapy consisting in a radiation converter from electrons to X-rays. Since X-rays penetrate deeper than the electrons from which they are generated, we used this technology in a configuration that delivers a uniform dose on large targets to irradiate insects for SIT aim. In this topic, we gained practical experience working with Aedes albopictus, a mosquito vector of various tropical diseases such as dengue and zika. Several dosimetric studies have been conducted to achieve male sterility without affecting male mating competitiveness in comparison with untreated males. Lower doses have been also tested on an Ae. albopictus strain modified with the bacterium Wolbachia, which also determines male sterility, to sterilize the females eventually escaping the sexing procedures preliminary to the releases of the males

Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells

Virus-specific CD8+ T cells are thought to play an important role in resolving acute hepatitis C virus (HCV) infection as viral clearance has been associated with a strong and sustained CD8+ T cell response. During the chronic state of HCV infection virus-specific T cells have a low frequency and a reduced responsiveness. Based on this, a therapeutic vaccine increasing the frequency of specific T cells is a promising alternative for the treatment of chronic HCV infection. We improved an existing vaccine platform based on immunopotentiating reconstituted influenza virosomes (IRIVs) for efficient delivery of peptide epitopes to the MHC class I antigen presentation pathway. IRIVs are proteoliposomes composed of phospholipids and influenza surface glycoproteins. Due to their fusogenic activity, IRIVs are able to deliver encapsulated macromolecules, e.g. peptides to immunocompetent cells. We developed a novel method based on chimeric virosomes [chimeric immunopotentiating reconstituted influenza virosomes (CIRIVs)] combining the high peptide-encapsulation capacity of liposomes and the fusion activity of virosomes. This new approach resulted in a 30-fold increase of the amount of incorporated soluble peptide compared with current preparation methods. To study the immunogenicity of chimeric virosomes HLA-A2.1 transgenic mice were immunized with CIRIVs containing the HCV Core132 peptide. Core132-CIRIVs efficiently induced specific cytotoxic and IFNγ-producing T cells already with low peptide doses. Vaccine formulations, which include combinations of different HCV-derived CTL epitopes could be used to induce not only a strong but also a multi-specific CTL response, making them potential candidates for therapeutic and maybe prophylactic T cell vaccines in human

Investigating the role of Armadillo-related proteins in early land plants

Mosses evolved approximately 500 million years ago and were among the earliest plants to make the transition from water to land. Mosses are therefore placed at an ideal evolutionary position in which to understand how plant physiology and development has evolved from simple unicellular aquatic organisms to generate the huge diversity of complex modern day flowering plants. The moss Physcomitrella has the unique ability among known land plants to carry out homologous recombination at a similar efficiency to the yeast Saccharyomyces cerevisiae. Armadillo-related proteins play important roles in cellular processes both in animals and plants. In Arabidopsis, ARABIDILLO1 and ARABIDILLO2 control root system architecture. ARABIDILLO-like proteins have been identified extensively throughout the plant kingdom, including early-evolving moss and agriculturally important crops such as rice and maize. Three Physcomitrella ARABIDILLO homologues have been identified; PHYSCODILLO1A, PHYSCODILLO1B and PHYSCODILLO2. Cloning, sequencing and Southern blotting approaches confirmed that PHYSCODILLO2 was a single copy gene, whereas full-length PHYSCODILLO1A and PHYSCODILLO1B genes were 100% identical and exist in a tail-to-tail orientation with 8kb separating their stop codons. A number of physcodillo deletion mutants have been generated. Phenotypic analyses revealed that PHYSCODILLO proteins appear to play important roles during early developmental processes, including growth of filaments from protoplasts and spore germination.EThOS - Electronic Theses Online ServiceGBUnited Kingdo

Beam commissioning of the 35 MeV section in an intensity modulated proton linear accelerator for proton therapy

This paper presents the experimental results on the Terapia Oncologica con Protoni-Intensity Modulated Proton Linear Accelerator (TOP-IMPLART) beam that is currently accelerated up to 35 MeV, with a final target of 150 MeV. The TOP-IMPLART project, funded by the Innovation Department of Regione Lazio (Italy), is led by Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) in collaboration with the Italian Institute of Health and the Oncological Hospital Regina Elena-IFO. The accelerator, under construction and test at ENEA-Frascati laboratories, employs a commercial 425 MHz, 7 MeV injector followed by a sequence of 3 GHz accelerating modules consisting of side coupled drift tube linac (SCDTL) structures up to 71 MeV and coupled cavity linac structures for higher energies. The section from 7 to 35 MeV, consisting on four SCDTL modules, is powered by a single 10 MW klystron and has been successfully commissioned. This result demonstrates the feasibility of a “fully linear” proton therapy accelerator operating at a high frequency and paves the way to a new class of machines in the field of cancer treatment

Case Study: LifeWatch Italy Phytoplankton VRE

LifeWatch Italy, the Italian node of LifeWatch ERIC, has promoted and stimulated the debate on the use of semantics in biodiversity data management. Actually, biodiversity and ecosystems data are very heterogeneous and need to be better managed to improve the actual scientific knowledge extracted, as well as to address the urgent societal challenges concerning environmental issues. LifeWatch Italy has realized the Phytoplankton Virtual Research Environment (hereafter Phytoplankton VRE), a collaborative working environment supporting researchers to address basic and applied studies on phytoplankton ecology. The Phytoplankton VRE provides the IT infrastructure to enable researchers to obtain, share and analyse phytoplankton data at a level of resolution from individual cells to whole assemblages. A semantic approach has been used to address data harmonisation, integration and discovery: an interdisciplinary team has developed a thesaurus on phytoplankton functional traits and linked its concepts to other existing conceptual schemas related to the specific domain

The Top-Implart Proton Linear Accelerator: Interim Characteristics of the 35 Mev Beam

In the framework of the Italian TOP-IMPLART project (Regione Lazio), ENEA-Frascati, ISS and IFO are developing and constructing the first proton linear accelerator based on an actively scanned beam for tumor radiotherapy with final energy of 150 MeV. An important feature of this accelerator is modularity: an exploitable beam can be delivered at any stage of its construction, which allows for immediate characterization and virtually continuous improvement of its performance. Currently, a sequence of 3 GHz accelerating modules combined with a commercial injector operating at 425 MHz delivers protons up to 35 MeV. Several dosimetry systems were used to obtain preliminary characteristics of the 35-MeV beam in terms of stability and homogeneity. Short-term stability and homogeneity better than 3% and 2.6%, respectively, were demonstrated; for stability an improvement with respect to the respective value obtained for the previous 27 MeV beam

Interactive Effect of UVR and Phosphorus on the Coastal Phytoplankton Community of the Western Mediterranean Sea: Unravelling Eco- Physiological Mechanisms

Versión del editor4,411